Senaste uppdateringen :
28/04/2024
Forskargrupper - Universidad Complutense de Madrid,Facultad de Farmacia   Pdf  
Spanien
Universitet
Universidad Complutense de Madrid,Facultad de Farmacia
Madrid
Hänvisningar   Hänvisningar   (12)  
1
Stability of daptomycin reconstituted vials and infusion solutions.
Ferrandez J, Sanchez R, Diaz D, Diaz M, Estevan M, Garcia T. (sanchez@salud.madrid.org)
EJHP - 2018 - ; 25: 107-110.
2
Stability of carboplatin infusion solutions used in desensitization protocol.
Vazquez-Sanchez R, Sanchez-Rubio-Ferrandez J, Cordoba-Diaz D, Cordoba-Diaz M, Molina-Garcia T. (rovazsan@hotmail.com)
J Oncol Pharm Practice - 2018 - 25,5:1076?1081
3
Compatibility and stability of ternary admixtures of tramadol, haloperidol, and hyoscine.
Negro S, Martin A, Azuara L, Sanchez Y, Barcia E. ()
J Palliat Med - 2010 - ; 13, 3: 273-277.
4
Tramadol and hyoscine N-butyl bromide combined in infusion solutions: compatibility and stability.
Barcia E, Martin A, Azuara ML, Sanchez Y, Negro S. (ebarcia@farm.ucm.es)
Support Care Cancer - 2007 - ; 15: 57-62.
5
Compatibility and stability of tramadol and dexamethasone in solution and its use in terminally ill patients.
Negro S, Salama A, S?nchez Y, AzuaraM.L, Barcia B. (soneal@farm.ucm.es)
J Clin Pharm Ther - 2007 - ; 32: 441-444.
6
Morphine, haloperidol and hyoscine N-butyl bromide combined in sc infusion solutions : compatibility and stability evaluation in terminal oncology patients.
Negro S, Reyes R, Azuara ML, Sanchez Y, Barcia E. (soneal@farm.ucm.es )
Int J Pharm - 2006 - ; 307: 278-284.
7
Compatibility and stability of furosemide and dexamethasone combined in infusion solutions.
Negro S, Rendon AL, Azuara ML, S?nchez Y, Fern?ndez-Carballido A, Barcia E. ( soneal@farm.ucm.es)
Arzneimittel Forschung - 2006 - ; 56, 10: 714-720.
8
Stability and compatibility of binary mixtures of morphine hydrochloride with hyoscine-n-butyl bromide.
Barcia E, Reyes R, Azuara L, Sànchez Y, Negro S. ()
Support Care Cancer - 2005 - ; 13, 4: 239-245.
9
Stability of tramadol and haloperidol for continuous infusion at home.
Negro S, Martin A, Azuara ML, Sanchez Y, Barcia E. ()
J Pain Symptom Manage - 2005 - ; 30: 192-199.
10
Stability study of an aqueous formulation of captopril at 1 mg/ml.
Escribano Garcia MJ, Torrado Duran S, Torrado Duran JJ. (torrado2@farm.ucm.es)
Farm Hosp - 2005 - ; 29: 30-36.
11
Compatibility of haloperidol and hyoscine-N-butyl bromide in mixtures for subcutaneous infusion to cancer patients in palliative care.
Barcia E, Reyes R, Azuara M.L, S?nchez Y, Negro S. ()
Support Care Cancer - 2003 - ; 11, 2: 107-113.
12
Physical compatibility and in vivo evaluation of drug mixtures forsubcutaneous infusion to cancer patients in palliative care.
Azuara ML, Sanchez Y, Reyes R, Barcia E. (soneal @eucmax.sim.ucm.es)
Support Care Cancer - 2001 -

 Förteckning över substanser   Molekyler Studerade   (11)  
Antihypertensivum Oral lösning Captopril
Cancerläkemedel Injektion Carboplatin
Antibiotikum Injektion Daptomycin
Antiinflammatoriskt medel Injektion Dexamethasone sodium phosphate
Diuretikum Injektion Furosemide
Neuroleptikum Injektion Haloperidol lactate
Antiemetikum Injektion Metoclopramide hydrochloride
Anxiolytikum Injektion Midazolam hydrochloride
Analgetikum Injektion Morphine hydrochloride
Antimuskarint medel Injektion Scopolamine N-butyl bromide
Analgetikum Injektion Tramadol hydrochloride

  Mentions Légales